MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts

MICA：利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略

• 批准号: MR/X00466X/1
• 负责人: Francesco Galli
• 金额: $ 51.79万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FX00466X%2F1
• 关键词: MICA; Strategy; heart; repair; Duchenne

The NHS official website indicates that around 70,000 people have Muscular Dystrophy (MD) or a related condition in the UK. Duchenne Muscular Dystrophy (DMD) is the most common and one of the most severe forms of MD. DMD is an inherited disease due to lack of expression of the dystrophin protein, causing a progressive waste of skeletal muscle which lead to progressive loss of ambulation, muscle weakness and muscle wasting in children. In the most severe cases, also heart muscle cells are affected, and this result in heart failure, the most common cause of premature death in DMD patients. All MDs still lack an effective therapy, even though administration of steroids (although with severe adverse effects), corrective surgery, assisted ventilation and drugs to support cardiac function have improved both the duration and the quality of life for patients.Many approaches based on either stem cells or gene therapy have entered clinical experimentation with the aim of repairing DMD heart, but none has reached significant clinical efficacy. The limited success of these therapies is due both to the difficulties of delivering the treatment to the heart and to the activation of the immune system of the patients towards donor cells or viral vectors. To overcome these limitations, I have developed a cell mediated exon skipping strategy, for skeletal muscle, currently being tested in a clinical trial in Manchester (EudrAct n.2019-001825-28), based upon transplantation of autologous Mesoangioblasts (Mabs), which are vessel-associated myogenic progenitors. Mabs are genetically corrected using a lentivector expressing a small nuclear RNA (snRNA) designed to induce exon-skipping on dystrophin exon 51 and to generate a short but functional version of dystrophin. The novelty of this approach is based on the ability of snRNA to diffuse along the regenerating muscle fibre and then correcting the resident dystrophic neighbouring nuclei inducing exon skipping. However, Mabs can be used only for the treatment of skeletal muscle as they cannot naturally differentiate into cardiac muscle: for this reason, the heart of the MD patients would remain untreated. In this project I will address this problem. It is well known that fibroblasts can be converted to cardiac muscle cells but, in comparison with Mabs, they cannot be delivered systematically, due to their inability to cross the vessel walls. This makes cardiac-converted fibroblasts good candidates to treat only localised lesions like myocardial infarct but not to treat progressive and widespread cardiomyopathies. My preliminary data show that Mabs can be converted to cardiomyocytes by transient over-expression of specific cardiac related genes in around 10-15 days. I therefore hypothesize that this time window will allow to deliver these Mabs-converted cardiomyocytes by cardiac catheterization in the whole heart. This project aims to evaluate the structural and functional amelioration of the heart in a mouse model of DMD after transplantation of Mabs-converted cardiomyocytes. Moreover, I will quantify the extent of the fusion of genetically corrected Mabs-converted cardiomyocytes with resident cardiomyocytes and subsequently the rate of correction, by exon-skipping, in the neighbouring nuclei quantifying the amount of dystrophin produced.The core element of this strategy is already in clinical experimentation for DMD skeletal muscle but not for the heart. This project will test the applicability of the cell mediated exon-skipping strategy to the heart. The succesful outcome of this project, demonstrating the efficacy of this strategy, will lead the way for a future clinical testing of this strategy in the heart of DMD patients and in heart diseases in general.

NHS官方网站显示，英国约有70，000人患有肌肉萎缩症（MD）或相关疾病。Duchenne肌营养不良症（DMD）是最常见和最严重的MD形式之一。DMD是一种遗传性疾病，由于缺乏肌营养不良蛋白的表达，导致骨骼肌的进行性浪费，从而导致儿童的进行性肌肉萎缩、肌无力和肌肉浪费。在最严重的情况下，心肌细胞也受到影响，这导致心力衰竭，这是DMD患者过早死亡的最常见原因。尽管类固醇激素（尽管有严重的副作用）、矫正手术、辅助通气和支持心脏功能的药物已经改善了患者的持续时间和生活质量，但所有的DMD仍然缺乏有效的治疗方法。许多基于干细胞或基因治疗的方法已经进入临床实验，目的是修复DMD心脏，但没有一种达到显著的临床疗效。这些疗法的有限成功是由于将治疗递送到心脏的困难以及患者的免疫系统对供体细胞或病毒载体的激活。为了克服这些局限性，我开发了一种细胞介导的骨骼肌外显子跳跃策略，目前正在曼彻斯特的一项临床试验中进行测试（EudrAct n.2019-001825-28），该策略基于移植自体成中血管细胞（Mesoangioblasts，Mab），这是血管相关的肌源性祖细胞。使用表达小核RNA（snRNA）的慢病毒载体对单克隆抗体进行遗传校正，所述慢病毒载体被设计为诱导肌营养不良蛋白外显子51上的外显子跳跃并产生短但功能性形式的肌营养不良蛋白。这种方法的新奇是基于snRNA能够沿着再生肌纤维扩散，然后纠正诱导外显子跳跃的常驻营养不良相邻核的能力。然而，单克隆抗体只能用于治疗骨骼肌，因为它们不能自然分化为心肌：因此，MD患者的心脏将保持未经治疗。在这个项目中，我将解决这个问题。众所周知，成纤维细胞可以转化为心肌细胞，但与单克隆抗体相比，由于它们不能穿过血管壁，它们不能被系统地递送。这使得心脏转化的成纤维细胞成为仅治疗局部病变如心肌梗死而不治疗进行性和广泛性心肌病的良好候选者。我的初步数据显示，单克隆抗体可以在大约10-15天内通过特定心脏相关基因的短暂过表达转化为心肌细胞。因此，我假设这个时间窗将允许通过心导管术在整个心脏中递送这些Mab转化的心肌细胞。本项目旨在评估移植Mabs转化的心肌细胞后DMD小鼠模型心脏结构和功能的改善。此外，我将量化的程度的融合基因校正MABS转换的心肌细胞与居民心肌细胞和随后的校正率，通过外显子跳跃，在相邻的核量化的量的肌营养不良蛋白produced.The核心要素，这一战略已经在临床实验DMD骨骼肌，但不是心脏。该项目将测试细胞介导的外显子跳跃策略对心脏的适用性。该项目的成功结果证明了该策略的有效性，将为该策略在DMD患者心脏和一般心脏病中的未来临床试验开辟道路。